Searched for
SYNERGIES IN PHARMA
Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health SciencesPharmaceuticals giant Cipla announced its merger with Inzpera Healthsciences Limited on Wednesday. This consolidation aims for more efficie...- RICE Adamas Group expands national footprint with Mumbai Office inaugurationAdamas University and Adamas Tech Consulting have launched a new Mumbai office and the Adamas School of Experiential Learning, offering 10-...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...
- Apollo Hospitals to spin off digi health, pharmacy businessApollo Hospitals is demerging its omnichannel pharma and digital health businesses into a new entity, aiming for a separate listing. This m...
- JB Chemicals shares fall over 6% as Torrent makes open offer at 9% discountJB Chemicals & Pharmaceuticals shares declined after KKR announced the sale of its stake to Torrent Pharma, valuing JB Pharma at Rs 25,689 ...
- Suven-Cohance Lifesciences merger announced to create 1st listed PE-led contract manufacturer in Indian pharmaSuven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is w...
- Government unveils National Policy on R&D in pharma, medtech"Today is a historic day, an inflection point in the journey of "Atmanirbharta" in the pharma and medical devices sector. We need to transf...
- Gland Pharma acquires French CDMO Cenexi for €120 millionFounded in 2004, Cenexi, along with its subsidiaries, is engaged primarily in the business of CDMO of pharmaceutical products with expertis...
- Biocon board approves sale of branded formulations business to subsidiaryThe Board of Directors in its meeting approved the sale of Branded Formulations India (BFI) business to Biocon Biologics India (BBIL).
- Brokerages see over 40% upside in Sun Pharma shares after 2-fold rise in consolidated Q2 net profitNet sales of the company increased by 13.20% YoY to Rs 7,764.03 crore for the quarter under review against Rs 6,585.16 crore in the same qu...
- Making Ranbaxy units cGMP compliant time consuming: Sun PharmaThe company expects to complete the remediation steps in at least one of these facilities in this fiscal, Sun Pharma Managing Director Dili...
- Buy Sun Pharmaceutical Industries Ltd., target Rs 925.0 : Motilal Oswal SecuritiesSun Pharma remains one of Motilal Oswal's top picks in the Indian pharma space on account of its multiple triggers (MK-3222 NDA filing, Ran...
- Ranbaxy integration: Sun Pharma may drop some non-strategic unitsSun Pharma may discontinue certain non-strategic businesses as part of its integration process with Ranbaxy Laboratories.
- Torrent Pharma board approves Zyg Pharma's amalgamationTorrent Pharmaceuticals today said its board has given nod to the scheme of amalgamation of its subsidiary Zyg Pharma with the company.
- Open to acquisitions but selective with targets: Sun PharmaSun Pharma says it is open to further acquisitions but will consider only targets "which will not require significant amount of management ...
- Need to regain trust of regulators post Ranbaxy deal: Dilip Shanghvi, Sun PharmaIn an interview with ET Now, Nirmal Jain, chairman, IIFL Group, and R Venkataraman, managing director, share their views on markets.
- Sun Pharma-Ranbaxy merger may put pressure on Ebitda margins of merged entity: Daljeet Singh KohliHow Sun Pharma integrates its business will be keenly followed, says Kohli. Merged entity will take some time to derive synergistic benefit...
- Sun Pharma rallies over 8%, breaches Rs 600 levels on Ranbaxy deal; top Sensex gainerAnalysts are betting around 20% return from the stock in the medium term. They say the stock could double investor wealth in two years.
- Ranbaxy to sell Daiichi Sankyo product in MalaysiaDrug firm Ranbaxy Laboratories and Japan's Daiichi Sankyo today said Ranbaxy will market its parent company's products in Malaysia.
Load More
